Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 37

    1.

    Recent Trends of Japanese Hepatocellular Carcinoma due to HCV in Aging Society.

    Hiraoka A, Hidaka S, Shimizu Y, Utsunomiya H, Imai Y, Tatsukawa H, Tazuya N, Yamago H, Yorimitsu N, Tanihira T, Hasebe A, Miyamoto Y, Ninomiya T, Kawasaki H, Hirooka M, Abe M, Hiasa Y, Matsuura B, Onji M, Michitaka K.

    Hepatogastroenterology. 2011 Dec 22;59(118). doi: 10.5754/hge11732. [Epub ahead of print]

    PMID:
    22193439
    [PubMed - as supplied by publisher]
    2.

    Optimization of Comorbidity Therapy to Achieve Sustained Viral Response in HCV Patients.

    Ucciferri C, Vecchiet J, Pizzigallo E, Falasca K.

    Hepatogastroenterology. 2011 Dec 22;59(117). doi: 10.5754/hge11541. [Epub ahead of print]

    PMID:
    22193374
    [PubMed - as supplied by publisher]
    3.

    Comparison of the hemodynamics between patients with alcoholic or HCV-related cirrhosis.

    Momiyama K, Nagai H, Sumino Y.

    Hepatogastroenterology. 2011 Nov-Dec;58(112):2036-40. doi: 10.5754/hge10121.

    PMID:
    22234075
    [PubMed - indexed for MEDLINE]
    4.

    Combination PEG-IFN a-2b/Ribavirin Therapy Following Treatment of Hepatitis C Virus-Associated Hepatocellular Carcinoma is Capable of Improving Hepatic Functional Reserve and Survival.

    Ishikawa T, Higuchi K, Kubota T, Seki K, Honma T, Yoshida T, Kamimura T.

    Hepatogastroenterology. 2012 Mar-Apr;59(114):529-32. doi: 10.5754/hge10867.

    PMID:
    22024226
    [PubMed - in process]
    5.

    Viral Decline Over 48h and HCV Amino Acid Mutations are Related to Efficacy of PEG-IFN/Ribavirin.

    Miyasaka A, Kumagai I, Abe K, Suzuki K.

    Hepatogastroenterology. 2012 May-Jun;59(115):794-9. doi: 10.5754/hge11570.

    PMID:
    22020909
    [PubMed - in process]
    6.

    CYP3A4*18 polymorphisms and anti-hepatitis A virus seroprevalence.

    Ahmad F, Che Hamzah NA, Mustaffa N, Hua GS.

    Hepatogastroenterology. 2011 Sep-Oct;58(110-111):1725-9. doi: 10.5754/hge11107. Epub 2011 Jul 15.

    PMID:
    21940338
    [PubMed - indexed for MEDLINE]
    7.

    Telaprevir for chronic hepatitis C with genotype 1: a meta-analysis.

    Dang SS, Wang WJ, Wang XF, Li YP, Li M, Jia XL, Wang Y, Liu E, Zhao S.

    Hepatogastroenterology. 2012 Mar-Apr;59(114):461-8. doi: 10.5754/hge11312.

    PMID:
    21940388
    [PubMed - in process]
    8.

    Ribavirin dose and treatment outcome of Korean patients with genotype 1 chronic hepatitis C.

    Sinn DH, Kim J, Shin SR, Gwak GY, Choi MS, Lee JH, Koh KC, Yoo BC, Paik SW.

    Hepatogastroenterology. 2012 Jan-Feb;59(113):1-6. doi: 10.5754/hge11387.

    PMID:
    21940368
    [PubMed - indexed for MEDLINE]
    9.

    Prediction of significant fibrosis in chronic hepatitis C patients with normal ALT.

    Park JJ, Park JY, Kim do Y, Park YN, Ahn SH, Chon CY, Han KH.

    Hepatogastroenterology. 2011 Jul-Aug;58(109):1321-7. doi: 10.5754/hge11041.

    PMID:
    21937403
    [PubMed - indexed for MEDLINE]
    10.

    Gamma-glutamyltranspeptidase in predicting sustained virological response in individuals with chronic hepatitis C.

    Coban S, Idilman R, Erden E, Tüzün A.

    Hepatogastroenterology. 2011 Jul-Aug;58(109):1301-6. doi: 10.5754/hge10625.

    PMID:
    21937399
    [PubMed - indexed for MEDLINE]
    11.

    Effects of simvastatin in patients with viral chronic hepatitis C.

    Mihaila RG, Nedelcu L, Fratila O, Retzler L, Domnariu C, Cipaian RC, Rezi EC, Beca C, Deac M.

    Hepatogastroenterology. 2011 Jul-Aug;58(109):1296-300. doi: 10.5754/hge08074.

    PMID:
    21937398
    [PubMed - indexed for MEDLINE]
    12.

    Chronic hepatitis C treated with peginterferon alfa plus ribavirin in clinical practice.

    Velosa J, Serejo F, Bana T, Redondo I, Simão A, Vale AM, Pires S, Macedo G, Marinho R, Peixe P, Sarmento J, Matos L, Calinas F, Carvalho A, Figueiredo A.

    Hepatogastroenterology. 2011 Jul-Aug;58(109):1260-6. doi: 10.5754/hge10239.

    PMID:
    21937391
    [PubMed - indexed for MEDLINE]
    13.

    The role of the gut barrier function in the pathophysiology of viral liver cirrhosis.

    Choi Y, Jeon WK, Hwang SJ, Kim BI, Sohn CI, Park DI, Cho YK, Kim HJ, Park JH.

    Hepatogastroenterology. 2011 Jul-Aug;58(109):1244-7. doi: 10.5754/hge10338.

    PMID:
    21937387
    [PubMed - indexed for MEDLINE]
    14.

    Failure to achieve 2-log10 viral decrease in first four weeks of peg-IFNalpha-2b plus ribavirin therapy for chronic hepatitis C with genotype 1b and high viral titer is useful in predicting non-response: evaluation of response-guided therapy.

    Ohkoshi S, Yamagiwa S, Yano M, Takahashi H, Aoki YH, Waguri N, Igarashi K, Sugitani S, Takahashi T, Ishikawa T, Kamimura T, Wakabayashi H, Watanabe T, Matsuda Y, Aoyagi Y.

    Hepatogastroenterology. 2011 May-Jun;58(107-108):965-70.

    PMID:
    21830425
    [PubMed - indexed for MEDLINE]
    15.

    HCV RNA in serum and peripheral blood mononuclear cells after successful interferon therapy.

    Mohamad HI, El-Bab HK, Kamal AM.

    Hepatogastroenterology. 2011 May-Jun;58(107-108):932-6.

    PMID:
    21830419
    [PubMed - indexed for MEDLINE]
    16.

    A cohort study to investigate hepatocellular carcinoma risk in hepatitis C patients.

    Wang CH, Mo LR, Chang KK, Lin RC, Kuo JJ.

    Hepatogastroenterology. 2011 May-Jun;58(107-108):904-8.

    PMID:
    21830414
    [PubMed - indexed for MEDLINE]
    17.

    Hepatitis C virus and the skin.

    Al-Ali J, Al-Mutari N, Ahmed el-SF.

    Hepatogastroenterology. 2011 May-Jun;58(107-108):880-6.

    PMID:
    21830409
    [PubMed - indexed for MEDLINE]
    18.

    Early effect of peginterferon alpha-2b plus ribavirin treatment on blood pressure and insulin resistance in patients with chronic hepatitis C.

    Taskoparan M, Serin E, Gokturk HS, Icer MO, Abaci K, Ozer B, Zumrutdal A, Yilmaz U.

    Hepatogastroenterology. 2011 May-Jun;58(107-108):875-9.

    PMID:
    21830408
    [PubMed - indexed for MEDLINE]
    19.

    Treatment of recurrent hepatitis C (genotype 1) with pegylated interferon alfa-2b and ribavirin combination and maintenance therapy.

    Testino G, Sumberaz A, Ansaldi F, Borro P, Leone S, Ancarani AO, Gentile R, Icardi G.

    Hepatogastroenterology. 2011 Mar-Apr;58(106):536-8.

    PMID:
    21661427
    [PubMed - indexed for MEDLINE]
    20.

    Diabetes may not affect outcomes in hepatocellular carcinoma after radio-frequency ablation.

    Chen WT, Macatula TC, Lin CC, Lin CJ, Lin SM.

    Hepatogastroenterology. 2011 Mar-Apr;58(106):551-7.

    PMID:
    21661430
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk